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Inferring Progression Models for CGH data
Abstract
MOTIVATION: One of the mutational processes that has been monitored genome-wide is the
occurrence of regional DNA Copy Number Alterations (CNAs), which may lead to deletion or
over-expression of tumor suppressors or oncogenes, respectively. Understanding the relationship
between CNAs and different cancer types is a fundamental problem in cancer studies. RESULTS: This
paper develops an efficient method that can accurately model the progression of the cancer markers and
reconstruct evolutionary relationship between multiple types of cancers using Comparative Genomic
Hybridization (CGH) data. Such modeling can lead to better understanding of the commonalities and
differences between multiple cancer types and potential therapies. We have developed an automatic
method to infer a graph model for the markers of multiple cancers from a large population of CGH data.
Our method identifies highly related markers across different cancer types. It then builds a directed
acyclic graph that shows the evolutionary history of these markers based on how common each marker
is in different cancer types. We demonstrated the use of this model in determining the importance of
markers in cancer evolution. We have also developed a new method to measure the evolutionary
distance between different cancers based on their markers. This method employs the graph model we
developed for the individual markers to measure the distance between pairs of cancers. We used this
measure to create an evolutionary tree for multiple cancers. Our experiments on Progenetix database
show that our markers are largely consistent to the reported hot-spot imbalances and most frequent
imbalances. The results show that our distance measure can accurately reconstruct the evolutionary
relationship between multiple cancer types. AVAILABILITY: All the code developed in this paper are
available at http: //bioinformatics.cise.ufl.edu/phylogeny.html. subtypes of the same cancer.
CONTACT: nirmalya@cise.ufl.edu.
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ABSTRACT
Motivation: One of the mutational processes that has been monitored
genome-wide is the occurrence of regional DNA Copy Number
Alterations (CNAs), which may lead to deletion or over-expression
of tumor suppressors or oncogenes, respectively. Understanding the
relationship between CNAs and different cancer types is a fundamental
problem in cancer studies.
Results: This paper develops an efficient method that can accurately
model the progression of the cancer markers and reconstruct
evolutionary relationship between multiple types of cancers using
Comparative Genomic Hybridization (CGH) data. Such modeling can
lead to better understanding of the commonalities and differences
between multiple cancer types and potential therapies. We have
developed an automatic method to infer a graph model for the markers
of multiple cancers from a large population of CGH data. Our method
identifies highly related markers across different cancer types. It then
builds a directed acyclic graph that shows the evolutionary history
of these markers based on how common each marker is in different
cancer types. We demonstrated the use of this model in determining
the importance of markers in cancer evolution. We have also developed
a new method to measure the evolutionary distance between different
cancers based on their markers. This method employs the graph
model we developed for the individual markers to measure the distance
between pairs of cancers. We used this measure to create an
evolutionary tree for multiple cancers.
Our experiments on Progenetix database show that our markers
are largely consistent to the reported hot-spot imbalances and most
frequent imbalances. The results show that our distance measure can
accurately reconstruct the evolutionary relationship between multiple
cancer types.
Availability: All the code developed in this paper are available at http:
//bioinformatics.cise.ufl.edu/phylogeny.html.
Contact: nirmalya@cise.ufl.edu
1 INTRODUCTION
This paper develops a systematic way of understanding the
progression of multiple types of cancers by analyzing aberrations
in gene copy numbers. Alterations in the tumor genome affects the
progression of tumors. It has been argued that the oncogenomic
evolution leaves characteristic signatures of inheritance, thereby
allowing to infer models of tumor progression by identification of
these signatures in genome-wide mutational data [3]. One of the
mutational processes that can be monitored genome-wide is the
occurrence of regional DNA Copy Number Alterations (CNAs), which
may lead to deletion or over-expression of tumor suppressors or
oncogenes, respectively.
The distribution of CNAs in a given cancer type is not random,
and alterations occur at recurrent locations. For a broad range of
cancers or subtypes of the same clinico-pathological cancer entity,
characteristic patterns of recurrent alterations have been observed [6]
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Fig. 1. A plot illustrating the copy number status of the CGH data for 121
cases belonging to the Retinoblastoma cancer type. The X-axis and the Y-
axis denote the genomic intervals and samples respectively. The gain and loss
alterations are plotted in green (light gray) and red (dark gray) respectively.
The vertical lines show four cancer markers. The twenty five irregularly spaced
vertical lines at the bottom of the plot shows the starting/ending positions of
the chromosomes, 1, 2, · · · , 22, x and y on the CGH data.
(see Figure 1). We call a CNA recurrent if it is found at the same
location in sufficiently large percentage of the observed samples. Such
recurrent alterations are also called markers. For example, Figure 1
highlights four markers. More than one set of alterations can trigger
the same type of cancer. In other words, a cancer type can have several
signatures. We call the disorder resulting from such alterations as
subtypes of the same cancer.
An important method for genome-wide CNA screening is
Comparative Genomic Hybridization (CGH) [13]. CGH is a
molecular-cytogenetic analysis technique for detecting regions with
genomic imbalances (gains or losses of DNA segments). Applying
microarray technology to CGH allows the simultaneous, sequence-
specific detection of the copy number state of thousands of individual
DNA fragments [21]. Raw data from CGH experiments is expressed
as the ratio of normalized fluorescence of tumor and reference
DNA. Normalized CGH ratio data surpassing predefined thresholds
is considered indicative for genomic gains or losses, respectively.
For chromosomal CGH, several ratio measurements are used for the
calculation of the regional copy number state [11], while for array
CGH various methods of averaging results from spatially related
measurements are used [10].Chromosomal and array CGH data has
proven an important resource for cancer cytogenetics [5, 8, 9, 18,
24, 12]. For the communication of chromosomal CGH results (on
which this paper is based), a reverse in-situ karyotype format [19] is
used, describing imbalanced genomic regions with reference to their
chromosomal location.
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Existing works infer tumor progression models based on genetic
events such as recurrent CNAs. Their models describe the
evolutionary relationship between events and consequently expose
the progression and development of tumors. One of the existing
works by Bilke et al. [3], focus on the progression of individual
recurrent alterations. The time complexity of this approach grows
exponentially with the number of cancer types. The Progenetix [2]
database contains 20 different cancer types. The total number of
cancer subtypes is even much larger than this. Liu et al. showed that
on the average, each cancer can be explained with around six different
marker sets [17]. Thus, if we assume that each cancer is triggered
by five different marker sets on the average, the number of cancer
subtypes in nature will easily exceed 100. This makes the method
by Bilke et al. impractical as its time complexity will exceed 2100
for this kind of dataset. A promising approach seems to consider the
whole set of alterations of a cancer and infer a model based on the
alteration patterns of different cancers. Its time complexity should also
be polynomial of the different working parameters.
Such models effectively utilize the molecular characters of cancers
and easily extend to large scale analysis.
Contributions. In this paper, our objective is to infer the progression
model for multiple cancers (or cancer subtypes) based on the patterns
of genetic alterations. (We will use term cancer subtype to denote
both cancer subtype or stage of cancer.) We assume that similar
evolutionary processes act on different cancers, so that closely related
cancers exhibit similar alteration patterns. We identify the aberration
patterns of a cancer based on the set of key recurrent CNAs in this
cancer.
This paper has two major technical contributions:
1. We propose a computational method to infer a graph model for the
markers of multiple cancers. We demonstrate the use of this model
in determining the importance of markers in cancer evolution.
2. We develop a new method to measure the evolutionary distance
between different cancers based on their markers. We use existing
distance matrix methods, such as Fitch-Margoliash, to infer
progression models for multiple cancers.
Our experiments on a Progenetix dataset with 5918 CGH cases
belonging to 23 clinico-pathological cancer categories (22 specific
entities and one ’other’) show that our markers are largely consistent
to the reported hot-spot imbalances and most frequent imbalances. We
also generate phylogenetic trees for 20 cancers entities and 58 cancer
subtypes. The results show that cancers with the same histological
compositions are well grouped together.
The rest of paper is organized as follows. Section 2 briefly
introduces the preliminary knowledge. Section 3 extends the Bilke
et al’s approach [3] to infer a graph model for markers and discusses
its use. Section 4 proposes the novel distance measure for multiple
cancers based on a set of markers. Section 5 presents the experimental
results and some observations. Section 6 concludes this paper.
2 PRELIMINARIES
In this section, we briefly introduce some preliminary knowledge
related to our proposed approach. Section 2.1 presents a brief
discussion on the relationship between recurrent CNAs and cancer.
In Section 2.2, we discuss the concept of markers, which define
the key recurrent CNAs in a cancer. In Section 2.3, we discuss an
approach proposed by Bilke et al. [3] which we extend for inferring
the progression of markers.
2.1 Markers and tumor development
Researchers have proposed a number of models to infer tumor
progression based on genetic alterations, including recurrent CNAs.
Vogelstein et al inferred a chain model of four genetic events for the
progression of colorectal cancer [25]. The presence of all four events
appears to be critical for colorectal cancer development. Desper et
al. proposed a branching tree model [5] and a distance-based tree
model [4] by assuming the recurrent CNAs as a set of genetic events
that take place in some order [5]. They inferred the models for renal
carcinoma to demonstrate the progression of genetic events in that
cancer type. Bilke et al. proposed a graph model based on the shared
status of recurrent CNAs among different stages of cancer [3]. They
found that the pattern of recurrent CNAs in neuroblastoma is strongly
stage dependent. Pennington et al. developed a mutation model for
individual tumors and constructed an evolutionary tree for each tumor.
They identified a consensus tree model based on the mutations shared
by a substantial fraction of the tumor population [20]. These and other
studies were successful in setting in context prior knowledge about the
role of individual cancer related genes.
2.2 Marker detection
Due to the overlap between neighboring genomic intervals [17],
recurrent alteration intervals usually accumulate together and form
a region of recurrent alterations, which we call recurrent region.
Given a set of samples that belong to the same cancer, a marker
is an independent key recurrent alteration representing a recurrent
region. Previously, we proposed a dynamic programming algorithm to
identify the best R markers for a set of CGH cases. We demonstrated
that our markers capture the aberration patterns well and improve the
clustering of CGH cases [17]. In Figure 1, we plot the four markers
identified in an example set of 121 CGH cases.
CGH data of an individual tumor can be considered as an ordered
list of status values, where each value corresponds to a genomic
interval (e.g., a single chromosomal band). The status can be
expressed as a real number (positive, negative, or zero for gain, loss,
or no aberration respectively). We use this strategy and represent gain,
loss, and no change with +1, -1, and 0 respectively. Figure 1 plots
CGH derived copy number data from 121 cases of Retinoblastoma.
The following notation is used for the rest of the paper:
• Genomic interval: Each chromosome in CGH data consists of an
ordered list of intervals called genomic interval. The value of a
genomic interval denotes the aberration type of that interval, which
can be 0, +1 and -1 for gain, loss or no aberration respectively.
• Segment: A segment is a contiguous array of intervals that
have same aberrant status values for all the contained genomic
intervals. Formally, sj [u, v] denotes a continuous run of intervals
{xju, xju+1, · · · , xjv} in chromosome sj that starts at the uth
interval and ends at the vth where xju = x
j
u+1 = · · · = xjv != 0,
xju−1 != xju, xjv+1 != xjv .
• Recurrent region: A recurrent region is a segment that is present
in sufficient number of samples of a cancer type.
• Recurrent alteration: A recurrent alteration is a single genomic
interval present in an recurrent region.
• Marker: A marker is a recurrent alteration that is selected by
a marker selection algorithm. If there is more than one recurrent
alteration in proximity, only one of them is selected as a marker.
Each marker m in a cancer is represented by an ordered pairs <p,
q>, where p and q denote the position (genomic interval) and the
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aberration type respectively. The aberration type of a marker is
either gain or loss, denoted by 1 or -1 respectively.
• Support: Let S be a set of N CGH cases {s1, s2, · · · , sN}. Let
xjd denotes the alteration value (i.e., 1, -1 or 0) for case j at the
dth genomic interval, ∀d, 1 ≤ d ≤ D, where D is the number of
genomic intervals. Let m =< p, q > be a marker. We denote the
independent support of sj tom as δ(sj ,m). Here, δ(sj ,m) = 1 if
and only if xjp = q. Otherwise, δ(sj ,m) = 0. We define the total
independent support value of marker mt as the sum of its support
from all the cases. Formally, Supt(m) =
PN
j=1 δ(sj ,m). We will
use term support to denote Supt(m) in this paper.
2.3 Tumor progression model
Bilke et al. proposed an approach of inferring a tumor progression
model for Neuroblastoma (NB) with four different subtypes from
CGH data [3]. They describe the relationship between different
subtypes based on the recurrent alterations shared by these subtypes.
Their idea first identifies a set of recurrent alterations. Each recurrent
alteration belongs to one of the following three categories: common
(shared by all the subtypes), shared (shared by two or more subtypes)
and unique (distinct to only one subtype). They propose a statistical
model to identify recurrent alterations and compute the shared status
of these alterations. Each shared status is a set of subtypes that contain
this recurrent alteration.
Fig. 2. Two examples of Venn diagram
(left) of two sets and its corresponding
graph model (right). The three sections
in the Venn diagram are denoted asA,B
andC respectively. In (a) both the cancer
types A and B have some common
markers and each contains additional
non-common markers. So they have
inherited from an unobserved common
subtype. In (b) the markers of A is a
proper subset of that of B. So B is a
derivative of type A.
The shared status of recurrent
alterations can be described
using a Venn diagram. For
example, Figure 2 shows
two Venn diagrams (left)
of two sets, represented by
two overlapping circles. Let
S1 and S2 denote the left
and right circle respectively.
There are three distinct areas
(denoted as sections) marked
by A, B and C in each
Venn diagram. Each section
represent a possible logical
relationship between the two
sets. For example, section
A and C represent S1 − S2
and S1 ∩ S2 respectively. A
section is called non-empty
if it contains some members.
Each non-empty section is
marked by a distinct color
in Figure 2. The component
of a non-empty section is
defined to be the sets whose
members are contained in
this section. For example,
the components of section A and C are {S1} and {S1, S2}
respectively. In general, the number of distinct sections S in a Venn
diagram of K sets can be as large as S = 2K − 1, which is also the
number of different shared status of a recurrent alteration between K
cancer subtypes. Since each section can be empty or non-empty, there
are totally 2S distinct Venn diagrams forK sets.
The authors build a Venn diagram of four sets for the four different
subtypes of NB. In the Venn diagram each set corresponds to one of
the four NB. The members of each set are the recurrent alterations
that belong to that subtype of NB. The intersection of two main sets
represents their shared recurrent alterations.
The authors proposed a graph model based on the structure of
Venn diagram to infer the progression of four different subtypes of
NB. The resulting graph is a directed acyclic graph with each vertex
corresponding to a non-empty section in the Venn diagram. An edge
connects from a vertex u to a vertex v if the recurrent alterations of
u is a subset of that of v and there is no vertex w whose markers are
a proper subset of that of v and a proper superset of that of u. The
number of vertices in the resulting graph is bounded by min{S, T},
where T is the number of recurrent alterations. For example, the graph
models corresponding to cancer subtypes in Figure 2 is shown on the
right of the figure. The authors demonstrate that, with the help of such
a model, it is possible to identify tumor progression in CGH data.
However, their approach has several limitations.
• First, their methods of calculating the shared status of each
recurrent alteration is very computational expensive. The time
complexity is exponential to the number of cancersK.
• This method can model the progression of markers. It, however,
can not model the evolutionary relationship among different cancer
types.
In addition to these limitations, Bilke et al do not provide a
systematic algorithm for mapping the Venn diagram to the graph
model automatically. These limitations make it impractical to use their
method for large scale datasets composed of many cancers.
3 PROGRESSION MODEL FOR MARKERS
In this section, we extend Bilke’s approach [3] to infer progression
models for markers of multiple cancer types. Studies of the evolution
of markers would be of obvious value to define gene loci relevant for
the early diagnosis or treatment of cancer. It helps to answer questions
about which marker tend to occur in many cancers, which markers are
likely to occur together etc. The main difference between our approach
and the previous work is that we focus on markers instead of every
recurrent alteration.
We compute the shared status of markers as follows. A marker
identified in one cancer type represents a recurrent alteration region
in this cancer type (Figure 1). However, for any two or more cancers
containing the same recurrent region, they may not have markers
identified at the same position due to the noise in the aberration
patterns. Therefore, markers in different cancers representing the same
recurrent region should be considered shared by these cancers.
First, we define the overlap coefficient between a marker and its
neighboring intervals. Let C denote a set of cases belonging to the
same cancer. Let m =< p, q > and d, 1 ≤ d ≤ D denote a marker
in C and a genomic interval respectively. For each case sj ∈ C, we
define Ej(d,m) = 1 if there exists a segment sj [u, v] overlapping
with both intervals d and p, i.e. u ≤ d, p ≤ v and xju = q, otherwise,
Ej(d,m) = 0. The function Ej(d,m) indicates that the alterations
at d and p belong to the same segment in sj and can be caused
by the same point-like genomic alteration. We compute the overlap
coefficient between d andm as
OC(d,m) =
P|C|
j=1 Ej(d,m)
Supt(m)
where |C| denotes the size of C and Supt(m) denotes the support
value of marker m in C. A large value of Cor(d,m) implies
that intervals p and d belong to the same recurrent region that is
represented by markerm.
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Next, we define that a marker m =< p, q > in cancer Ci is
shared by Cj if and only if the following condition is reached: there
is a marker m′ =< p′, q′ > in cancer Cj such that q′ = q and
OC(p,m′) > ", where " is a user-defined threshold. The larger is
the value of ", the harder that a marker is shared among multiple
cancers due to noise in the data. Intuitively, this definition indicates
that a marker mi in Ci is shared by another cancer Cj if there exists
a marker mj in Cj such that mj is highly overlapped with mi. To
compute the shared status of a marker in Ci, we visit every cancer
other than Ci. This makes the time complexity linear in the number of
cancers K. We denote the shared status S(m) of a marker m as the
set of cancers that share this marker, i.e. S(m) ∈ P({C1, · · · , CK}),
where P denotes the power set operation.
We propose an algorithm that generates a progression model for
K cancers based on markers. The progression model generated by
our algorithm is a directed acyclic graph. Each node of this graph
corresponds to a non-empty set of markers. The set of markers
corresponding to different nodes of this graph do not intersect. Our
algorithm consists of three steps:
• First step: We identify an optimal set of R markers for each
cancer using our marker identification program [17]. These markers
represent significant recurrent alterations specific to each cancer.
• Second step: For each marker in each cancer, we compute the
shared status of this marker using the method we described above.
If some markers in multiple disease entities are identical (both
position and type), we think them as a single marker and compute
its shared status once.
• Third step: The logical relationship between K cancers
corresponds to a Venn diagram of K sets. There are totally S =
2K − 1 distinct sections in this Venn diagram. Given a marker m
with shared status S(m), the section corresponding to S(m) is non-
empty. We mark all the non-empty sections in the Venn diagram
based on the shared status of all markers. We then convert the Venn
diagram to a graph model as follows. We create a vertex V for
each non-empty section and associate it with the markers whose
shared status corresponds to this section. We define the height of
this vertex, denoted as H(V ), as the number of components in
the corresponding section. We visit the vertices in the descending
order of their heights. For each pair of vertices Vi and Vj , H(Vi) <
H(Vj) , we create an edge from Vi to Vj if both of the following
conditions hold:
1. The component set of the section corresponding to Vi is a true
subset of that of Vj .
2. There is no other vertex Vk such that the component set of the
section corresponding to Vk is a superset of that of Vi and a
subset of that of Vj .
We analyze the time complexity of this algorithm as follows. The
time complexity of the first step is O(DNR) as analyzed in our
previous work [17], where D and N denote the number of genomic
intervals and number of cases of allK cancers respectively. The time
complexity of the second step isO(TNR), where T is the cardinality
of set consisting of the union of all markers. In the third step, the
number of vertices is bounded bymin{S, T}. Since T ≤ K ×R, the
time complexity of this step is O(K2R2) in the worst case. Since we
have D ≥ T , the overall time complexity is O(DNR) +O(K2R2).
In general, we have D * R,N * K2, the overall time complexity
can be written as O(DNR).
The graph created by our algorithm can be used to describe
the hierarchical or evolutionary relationship between markers
representing multiple stages between a single cancer type or among
the markers of different cancer types. We term a node as a root
node if it does not have any incoming edges. The nodes that are
close to a root (there can be multiple roots) denote the aberrations
that started in earlier stages. From this perspective, markers are not
equally important. The markers that are parents of other markers in
the hierarchical representation are common to multiple cancers. Thus,
difference at parent marker positions should contribute more to the
distance between different cancers than the child markers.
4 PROGRESSION MODEL FOR CANCERS
The aberration pattern defines the molecular characteristics of a
cancer. We assume that cancers with similar aberration patterns
are close to each other in the evolutionary history. The proper
identification of the similarities between cancers will expose the
underlying mechanism of cancer development and benefit the
diagnosis and treatment of cancers.
Phylogenetic tree is a simple and efficient model that infers
evolutionary relationship among three or more cancers. A key
challenge that needs to be addressed to employ existing distance
matrix methods for tree construction is to find a biologically
meaningful distance function between cancers. Next, we propose a
novel measure for computing the distance between cancers based
on their aberration patterns. Since markers are a set of recurrent
alterations that define the aberration patterns of a cancer, our
distance measure computes the distance between cancers based on
their markers. Formally, let Ci and Cj denote two cancers. Let
Mi = {mi,1, · · · ,mi,R} and Mj = {mj,1, · · · ,mj,R} denote the
corresponding R markers identified in Ci and Cj respectively, where
pi,1 < pi,2 < · · · < pi,R and pj,1 < pj,2 < · · · < pj,R. Please note
that pi,k may not equal to pj,k for any 1 ≤ k ≤ R. To compute the
distance between Ci and Cj , we first align the markers inMi to those
inMj . The goal of this alignment is to mapMi andMj into two high
dimensional vectors Mˆi and Mˆj ∈ Rg , where g ≤ 2R is the number
of dimensions of the new vectors, such that the new vectors contain
consensus information about pattern of alterations in Ci and Cj .
We say that a pair of markersmi,k andmj,r are overlapping if they
satisfy either one of the following two conditions:
1. Both markers appear at the same interval and have the same type,
i.e. pi,k = pj,r and qi,k = qj,r
2. Both markers represent the same region of recurrent alterations, i.e.
OC(pi,k,mj,r) > " and OC(pj,r,mi,k) > ", where " is a user-
defined threshold for overlap constraint.
In Section 3, we argue that markers are not equally important
in the progression of cancers. A marker that is common to many
cancers usually represents a fundamental characteristic of cancers.
Therefore, we assume that markers shared by many cancers are more
important than those shared by a few cancers. The intuition behind this
reasoning can be explained as follows. A marker that triggers most
of the cancers has survived the evolution of cancer progression with
high likelihood. The markers that are cancer specific have most likely
appeared later in the evolutionary history and created the underlying
cancer alteration pattern. As a result, the deviation in genomic
alterations corresponding to older markers corresponds to larger
distance between two cancer types as the age of the genomic alteration
increases. We incorporate this idea into the mapping process. We
assign weights to markers in each cancer. The weight of a marker is the
number of cancers that share this marker. LetWi = {wi,1, · · · , wi,R}
andWj = {wj,1, · · · , wj,R} be the vectors of weights for markers in
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Mi and Mj . Here, wi,k and wj,k denote the weights the kth marker
inMi andMj .
The mapping process works as follows. Each time we pick up a
pair of markers from Mi and Mj . We add a pair of new dimensions
to Mˆi and Mˆj respectively. The values of the added dimensions are
determined by three attributes of markers: support, weight and type.
Let ∆(mi,k) = Supt(mi,k) × wi,k × qi,k. If the two markers are
overlapping, the values added into Mˆi and Mˆj are ∆(mi,k) and
∆(mj,r) respectively. If two markers are not overlapping, we focus on
the marker at a smaller genomic interval. Without loss of generality,
we can assume pi,k < pj,r . There is no marker at interval pi,k in
Cj . However, we need to compute the information of this interval
across both cancers so that the difference of this interval can be taken
into account. So we assume that there is a ”hypothetical” marker at
pi,k in Cj . This marker is of the same type and weight as mi,k.
However, the support of this marker is computed based on the samples
in Cj . Let m′ =< p′, q′ > in Cj denote this hypothetical marker.
We have p′ = pi,k, q′ = qi,k and w′ = wi,k. Please note that
Supt(m′) depends on the alteration pattern in Cj and may not equal
to Supt(mi,k). We add the two values,∆(mi,k) and∆(m′), into Mˆi
and Mˆj respectively. Next, we choose another pair of markers and
repeat the above procedure until all the markers have been processed.
The algorithm of the mapping process of two sets of markers is
implemented as follows.
Inputs: Mi = {mi,1, · · · ,mi,R} and Mj = {mj,1, · · · ,mj,R}
where pi,1 < pi,2 < · · · < pi,R and pj,1 < pj,2 < · · · < pj,R.
Wi = {wi,1, · · · , wi,R} andWj = {wj,1, · · · , wj,R} are the vectors
of weights for markers inMi andMj
1. Initialize: Mˆi = Mˆj = []; k = r = 1;
2. while k ≤ R and r ≤ R
a. ifmi,k andmj,r are overlapping
Mˆi = [Mˆi,∆(mi,k)]; Mˆj = [Mˆj ,∆(mj,r)]; k = k + 1;
r = r + 1;
b. else if pi,k < pj,r
Create a hypothetical marker m′ same as mi,k in Cj ; Mˆi =
[Mˆi,∆(mi,k)]; Mˆj = [Mˆj ,∆(m′)]; k = k + 1
c. else if pi,k > pj,r
Create a hypothetical marker m′ same as mj,r in Ci; Mˆi =
[Mˆi,∆(m′)]; Mˆj = [Mˆj ,∆(mj,r)]; r = r + 1
d. else
Mˆi = [Mˆi,∆(mi,k)]; Mˆj = [Mˆj ,∆(mj,r)]; k = k + 1; r =
r + 1
3. while k ≤ R
Create a hypothetical marker m′ same as mi,k in Cj ; Mˆi =
[Mˆi,∆(mi,k)]; Mˆj = [Mˆj ,∆(m′)]; k = k + 1
4. while r ≤ R
Create a hypothetical marker m′ same as mj,r in Ci; Mˆi =
[Mˆi,∆(m′)]; Mˆj = [Mˆj ,∆(mj,r)]; r = r + 1
Outputs: Mˆi, Mˆj
Once we have the aligned vectors Mˆi and Mˆj , we use Extended
Jaccard coefficient [23] to compute the similarity between the two
vectors. Extended Jaccard coefficient is widely used as a similarity
measure in vector spaces. It retains the sparsity property of the cosine
similarity while allowing discrimination of collinear vectors. For
example, given two vectors Mˆi = [0.1, 0.3] and Mˆj = [0.2, 0.6], the
cosine similarity does not discriminate the difference between them
and the similarity value is computed as 1. However, in our case, Mˆi
and Mˆj are different because they denote recurrent alterations in Ci
and Cj with different frequencies. The Extended Jaccard coefficient
is computed as follows.
EJ(Mˆi, Mˆj) =
Mˆi · Mˆj
‖Mˆi‖2 + ‖Mˆj‖2 − Mˆi · Mˆj
The Extended Jaccard coefficient of any two vectors takes value
within the range of [0, 1]. It is easy to convert Extended Jaccard
coefficient to distance by subtracting it from one, i.e. D(Ci, Cj) =
1 − EJ(Mˆi, Mˆj). We compute the distance D(Ci, Cj) for any
1 ≤ i, j ≤ R. As a result, we construct the distance matrix for K
cancers. We apply existing distance matrix method, such as UPGMA,
to construct the phylogenetic tree.
5 EXPERIMENTAL RESULTS
Dataset: With 15,127 cases from 571 publications as of Dec 2007,
Progenetix is the largest resource for published chromosomal CGH
data [2] (http://www.progenetix.net/). For the purpose of
this paper, we use a dataset with 5,918 clearly malignant epithelial
neoplasias (ICD-O-3 xxxx/2 and xxxx/3), a descriptive overview
of which had been published previously [1]. From the biomedical
perspective, this dataset could be divided into 22 clinico-pathological
disease categories. Additional entities consisting of less than 40 cases
each were summarily moved to an ‘other’ category.
As result of the Progenetix database format transformation, for each
case the genomic imbalance status for 862 ordered intervals had been
extracted from the karyotype annotation. This information represents
the whole genome copy number status information, in the maximum
resolution feasible for cytogenetic methods. The value of each interval
is 1, -1 or 0, indicating the gain, loss and no change status. We have
used the cases corresponding to 20 different carincomas in this dataset.
The number of cases for these carincomas vary from 42 to 640.
The details of the dataset is shown in Table 1 of the supplementary
materials. For simplicity, we use the following abbreviations for
some of these carincomas. CRC: Colorectal adenocarcinoma, HCC:
Hepatocellular adenocarcinoma, HNSCC: Head-neck squamous cell
carcinoma, NSCLC: Non-small cell lung carcinoma, ES: Esophagus
carcinoma, RCC: Renal carcinoma, NPC: Nasopharynx carcinoma,
NE: Neuroendocrine carincoma and carcinoid, MEL: Melanocytic,
PAC: Pancreas adenocarcinoma, SCLC: Small cell lung carcinoma.
System specifications: We developed our code using MATLAB and
ran our experiment on a system with dual 2.59 GHz AMD Opteron
Processors, 8 gigabytes of RAM, and a Linux operating system.
5.1 Results for marker models
In this experiment, we infer a progression model for markers. We
perform each step one by one and discuss the results of each step as
follows. In the first step, we identify an optimal set of 20 markers
for each cancer. We use the marker selection algorithm from Jun et.
al [17]. The number of markers is decided based on observation by
Baudis et. al [1] that most of the cancer subtypes can be effectively
represented by around twenty markers. Please note that we exclude
100 (peri) centromeric intervals because 1) they mostly consist of
repetitive sequence (ALU repeats etc.) without encoding genes; 2)
they have technical or interpretation difficulties. The markers are
identified from the remaining 762 intervals.
An existing work by Baudis has identified the imbalance hot spots in
clinico-pathological entities in the same dataset [1], using an ‘average
profile’ based approach. We compared our markers to the reported
imbalance hot spots for validation test. Due to the limitation of space,
5
Liu et al
here we only present the comparison results for HNSCC disease
category.
• Imbalance hot spots identified by Baudis [1]:
gains: 3q26 (59.2%), 8q24 (40.8%), 11q13 (31.9%, many
specific high-level), 5p (26.5%), Xq, 1q, 7q(21), 12p, 17
losses: 3p (30.1%), 18q(22) (22.4%), 9p (22.4%), 11q24
(19.2%), 4, 5q, 8p, 13
• Markers identified by our method:
gains: 3q26.2 (57.2%), 8q24.3 (41%), 11q13.4 (31.9%), 5p14.3
(26.5%), Xq28 (23%), 7q21.3 (20.9%), 12p13.1 (17.7%), 17q25.3
(17.7%), 20q12 (17.7%), 19p13.11 (16.8%), 1q31.3 (16.2%),
18p11.23 (15.9%)
losses: 3p26.3 (30.7%), 18q23 (22.7%), 9p23 (22.4%), 11q25
(19.2%), 4p14 (18%), 5q21.3 (15.3%), 8p23.3 (16.2%), 13q21.33
(16.5%)
In the above results, markers or hot-spots are listed with detailed
locus and frequency information. Gains and losses are evaluated
separately. The hot-spots or markers are sorted in descending
frequency of occurrence. We identify markers as individual intervals
while Baudis identified the regional hot-spots from summary data.
Our results are highly compatible to reported results if we consider a
marker as a representative of a region. We successfully identify all the
hot spots identified by Baudis. We also identify additional hot-spots
(e.g., 18q23) that has significant support.
In the second step, for each disease entities, we compute the shared
status of each marker identified in this cancer using the method we
described in Section 3. We set the threshold " to 0.8. We tried with
different values for " and used 0.8 as it was giving best results.
However, We believe that our method is not too sensitive in terms
of those parameters, if we select those parameters from the near
neighborhoods of the given values. To compare with the reported
most frequent imbalances over all cancers, we analyze the markers
that are in the same regions. The comparisons of imbalance with top
frequencies are shown as follows.
• Most frequent imbalances reported by Baudis [1]:
+8q: ubiquitously high (exception NE and thyroid)
• Markers identified by our method and their shared status:
+8q23.1, +8q23.2, +8q23.3: 19 cancers (exception thyroid)
+8q24.13, +8q24.23, +8q24.3: 18 cancers (exception NE and
thyroid)
• Most frequent imbalances reported by Baudis [1]:
-13q: occurring in most carcinoma types (exception cholangio
and SQS)
• Markers identified by our method and their shared status:
-13q21.1, -13q21.2, -13q21.33: 18 cancers (exception CRC,
gastric, cholangio and SQS)
-13q22.3: 15 cancers (exception SCLC, CRC, prostate, thyroid,
gastric, cholangio and SQS)
The results show that our approach discovers the most frequent
markers in a consistent way to Baudis’ work. Please note that markers
are individual intervals instead of chromosomal regions. Additionally
to the markers reported by Baudis et al. as top-scorers in the different
entities, our method detected other regions, for example +17q and +7p
which both are shared by more than 12 cancers types.
In the third step, we build a graph model based on the shared
status of markers. The model contains 119 vertices and 385 edges,
which makes it hard to display in this paper’s format. However, we
Table 1. Quality of the phylogenetic trees according to three different criteria;
NMI, entropy and parsimony. Large NMI value and small entropy and
parsimony values are desirable. The numbers printed in bold show the best
result obtained among all trees in each category.
Tree construction Markers Quality of the trees
method NMI Entropy Parsimony
Fitch-Margoliash weighted 0.68 0.69 8unweighted 0.62 0.82 9
Neighbor joining weighted 0.67 0.81 9unweighted 0.69 0.74 9
UPGMA weighted 0.67 0.80 10unweighted 0.60 0.89 10
have uploaded the graph in a tabular format in a separate file as
a supplementary material. In that file, each entry corresponds to a
vertex. Each vertex is a set of markers that are shared by some cancer
subtypes. The model conveys useful information about the importance
of markers. We use this information in our next experiments in
Section 5.2.
5.2 Results for phylogenetic models
In this experiment, we infer progression models for cancer subtypes
using the distance-based approach described in Section 4. We
compute the distance matrix of 20 cancers listed in Table 1 of
the Supplementary Materials based on the markers reported in
Section 5.1. We test three different tree construction method,
namely Fitch-Margoliash, neighbor joining and UPGMA in PHYLIP
package [7].
Quantitative evaluation. Our first experiment measures the effect of
computing the distance between cancers based on the importance of
markers on phylogenetic tree construction. To do this, we construct
phylogenetic tree with and without assigning weights to markers. We
then label each cancer type with the histology group it belongs to. We
quantitatively evaluate the goodness of each tree using three different
measures:
• NMI. This metric measures how well a given set of clusters
separate labeled data. It takes values in [0, 1] interval, where 1
shows perfect separation. We measure the NMI at each internal
node by considering the nodes in its left and right subtree as two
clusters. We report the average NMI of all internal nodes.
• ENTROPY. Shannon’s entropy of an internal node of a tree measures
the uniformity of the labels of all the nodes of the subtree rooted at
it. It takes values in [0, 1] interval, where 0 shows that all the nodes
have the same label.
• PARSIMONY. This value shows the minimum number of unit
mutations needed explain a given phylogenetic tree. The unit
mutation in this tree changes one histology label to another.
Table 1 shows the average quality of all the trees we tested. Several
observations follow from these results. First, Fitch-Margoliash
produces the best tree in terms of entropy and parsimony. It is the
second to the neighbor joining in terms of NMI, but the difference
is little between the two. Particularly, we observe significant
improvement in terms of the parsimony measure. The definition of
parsimony measure implies that the probability of having a tree is
exponential in the number of mutations needed for that tree. Assume
that, on the average, the probability of mutating the genes to transform
the cancer in one histology to another is p. Then the likelihood of the
UPGMA tree is p2 times that of the Fitch-Margoliash tree as UPGMA
requires two more mutations. Our final important observation from
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this table is that weighing the markers often improves the quality of
the trees. The exception was the neighbor joining algorithm, where
the quality drop was not big.
Qualitative evaluation. From Table 1, we conclude that the Fitch-
Margoliash method with weighted markers produces the best tree. We,
thus use this method in the rest of this section.
Figure 3 shows the phylogenetic tree constructed on all cases of
all cancer types. The leaf nodes of the trees correspond to cancers
(e.g. clinico-pathological cancer entities). We mark these cancers
using different colors as well as capitalized letters based on the
histological composition of majority of cases in this cancer. Each color
corresponds to a capitalized letter. Different colors (letters) encode
different histological compositions of cancers. The internal nodes
represent hypothetical cancers. Since these intermediate cancers may
contain daughter branches from completely different histological, they
have to be viewed as common biological feature sets rather than truly
occurring clinico-pathological cancer entities.
ovarian {D}
NPC {C}
prostate {D}
MEL {G}
uterus {D}
HCC {D}
breast {D}
PAC {D}
CRC {D}
gastric {D}
bladder {F}
thyroid {A}
NE {A}
RCC {A}
ES {E}
SCLC {B}
NSCLC {E}
cervical {E}
vulva {C}
HNSCC {C}
Fig. 3. Phylogenetic tree of 20 cancer
entities. The labels/colors indicate the
following histologies. A: endocrine and
clear, B: small cell neuroendo, C:
squamous, D: adenocarcinomas, E:
mixed squamous/adeno, F: transitional,
G: melanoma.
The phylogenetic tree in
Figure 3 organizes cancer
types with same histological
composition closely in the
same subtree for many of
the cancer types. This correlation
is in concordance with the
view that cancer clones may
arise from tissue-specific cancer
stem cells [22], with a
similar regulatory program
targeted by genomic aberrations
in related tissues.
To strengthen the claim
that cancers that are in
proximity in the phylogenetic
tree are closely related we
refer to available literature.
First we focus on cancers
with same histologies. According
to Lee et. al [16] PIK3CA
gene, which is an oncogene,
is frequently mutated in
breast carcinomas and hepatocellular
carcinomas. Katoh et. al [14]
suggests a similarity of gastric
and colorectal adenocarcinoma
in terms of GSTM1 and
GSTT1 genetic polymorphism.
An obvious question is whether
similar evidences exist for
the cancer types that belong
to different histologies, but
are located closely in the
phylogenetic tree. Indeed,
Kurzrock et. al [15] shows
that abnormalities in the PRAD1 (CYCLIN D1/BCL-1) oncogene are
frequent in cervical and vulvar squamous cell carcinoma cell lines.
Running time results. We executed our code on a Linux machine
with Intel Xeon 2.7 GHz processor and 5 GB RAM. The first step
that uses Rsim for clustering ran for almost six hours. The second
step that generates the progression model of markers completed in
fifteen minutes. The next step, that saves the distance matrix for all
cancer entities required thirty minutes. The final step, that generates
the phylogeny model for the cancer types required a few seconds. The
entire program completed in seven hours.
Due to space limitations we report further experimental results
that analyze a subtree of the phylogenetic tree in Figure 3 in
Supplementary Materials.
6 CONCLUSIONS
We have developed an automatic method to infer a graph model for the
markers of multiple cancers. We demonstrated the use of this model
in determining the importance of markers in cancer evolution. We
also developed a new method to measure the evolutionary distance
between different cancers based on their markers. We used this
measure to create an evolutionary tree for multiple cancers.
With the application of our modeling approach to a set of more than
4600 epithelial neoplasias (carcinomas) with genomic imbalances, we
can draw some preliminary conclusions:
1) Marker determination and marker dependent subset generation
are powerful tools for structuring large CGH data sets.
2) Phylogenetic modeling of 58 cancer subtypes with unique
genomic marker sets shows a high concordance between branch
association and histological subtype
3) Cancer subtypes with a high level of genomic instability have
overall similar imbalance patterns, which may reflect their origin from
earlier, less determined progenitor cells and/or tissue independent
mechanisms responsible for high-order genomic instability.
The important oncogenomic result of our work is the description
of a closer relation between some tumor subsets/entities, which is
related to rough histopathological grouping (e.g. adenocarcinomas
vs. squamous cell). This goes beyond the single gene aberrations
described before, and supports statements made by us based on
frequency based clustering [1].
While our approach as described here used rough histological
group classification as a reference, a refined data set combined
with different reference qualities (e.g. clinical parameters) should
provide a significant contribution to the overall perception of genomic
instability in cancer development.
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